In­cyte's rux­oli­tinib scores its sec­ond ap­proval in two days, this time in chron­ic graft-ver­sus-host dis­ease

A day af­ter ap­prov­ing a top­i­cal for­mu­la­tion of In­cyte’s cash cow rux­oli­tinib for atopic der­mati­tis, reg­u­la­tors are back with more good news for the com­pa­ny’s fa­vorite JAK in­hibitor.

The FDA has giv­en Jakafi, the oral ver­sion of the drug, the green light to treat chron­ic graft-ver­sus-host dis­ease af­ter one or two lines of sys­temic ther­a­py, In­cyte said Wednes­day, mark­ing the drug’s sec­ond ap­proval in just as many days.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER